Search results for "PTEN"

showing 10 items of 211 documents

PTEN hamartoma tumor syndromes in childhood: description of two cases and a proposal for follow-up protocol

2013

PTEN hamartoma tumor syndromes (PHTS) are a spectrum of hamartomatous overgrowth syndromes associated with germ-line mutations in the tumor suppressor PTEN gene located on 10q23.3. It is widely accepted that two of these disorders, Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome, are allelic conditions. Because PTEN mutations are not identifiable in every case of the PHTS phenotype, the inability to detect a mutation within the PTEN gene does not invalidate the clinical diagnosis of Cowden syndrome, or Bannayan-Riley-Ruvalcaba syndrome, in patients who meet diagnostic criteria for these disorders. PTEN mutations are associated with an increased risk for developing breast, thyroid, end…

OncologyPTENmedicine.medical_specialtymedicine.disease_causeBannayan–Riley–Ruvalcaba syndromeSettore MED/38 - Pediatria Generale E SpecialisticaInternal medicineGeneticsmedicinePTEN Hamartoma tumor syndromeHamartomaPTENAllelePTEN Hamartoma tumor syndromes; PTEN gene; Cowden syndrome; Bannayan-Riley-Ruvalcaba syndromGenetics (clinical)Bannayan-Riley-Ruvalcaba syndromMutationbiologybusiness.industryThyroidCancerCowden syndromeCowden syndromePTEN genemedicine.diseasemedicine.anatomical_structureSettore MED/31 - OtorinolaringoiatriaSettore MED/03 - Genetica Medicabiology.proteinCancer researchbusiness
researchProduct

Pharmacogenomics of cetuximab in metastatic colorectal carcinoma

2014

Cetuximab is a chimeric monoclonal antibody that has revolutionized the treatment of metastatic colorectal cancer. Knowledge of the mechanisms that underlie its effectiveness, as well as the primary and secondary resistance mechanisms, have led to important developments in the understanding of cetuximab biology. In light of knowledge gained from recent trials, the efficacy of cetuximab has been clearly demonstrated to depend upon RAS mutational status, moreover cetuximab should only be used in a subset of patients who may benefit. In this article, we critically review clinical and pharmacogenetic issues of cetuximab, focusing on the cost–effectiveness involved with the use of the drug.

OncologySettore MED/06 - Oncologia MedicaCost effectivenessColorectal cancercost-effectiveneCetuximabColorectal NeoplasmPharmacologyAntineoplastic AgentPhosphatidylinositol 3-KinasesMutational statusMedicineNeoplasm MetastasiscetxuximabProto-Oncogene ProteinTOR Serine-Threonine KinaseCetuximabPharmacogeneticTOR Serine-Threonine KinasesNeoplasm MetastasiErbB ReceptorsMolecular MedicineColorectal NeoplasmsHumanmedicine.drugProto-Oncogene Proteins B-rafmedicine.medical_specialtypharmacogenomicEGFRAntineoplastic AgentsAntibodies Monoclonal HumanizedresistanceProto-Oncogene Proteins p21(ras)Geneticcolorectal carcinomaProto-Oncogene ProteinsInternal medicineGeneticsHumanspredictivecost-effectivenessneoplasmspharmacogenomicsPharmacologybusiness.industryPTEN Phosphohydrolaseras Proteinmedicine.diseasedigestive system diseasesDrug Resistance NeoplasmPharmacogeneticsPharmacogenomicsMutationras ProteinsReceptor Epidermal Growth FactorPhosphatidylinositol 3-KinasebusinessProto-Oncogene Proteins c-aktPharmacogeneticsRASPharmacogenomics
researchProduct

Response to Stanich et al.: Correspondence regarding-PTEN hamartoma tumor syndromes in childhood-Description of two cases and a proposal for follow-u…

2014

The follow-up protocol, which we describe in this study can serve as a practical proposal for clinicians, and as a basis for future studies. We strongly urge the clinician to start an early surveillance of the gastrointestinal tract including regular endoscopy. The main management goals in PHTS patients are to detect colon cancer early, and to prevent polyp-related complications (bowel obstruction from intussusception). The presence of multiple nonmalignant polyps in patients with PTEN mutations may complicate noninvasive methods of colon evaluation [Tan et al., 2012]. In addition, there is a high variability in severity of polyps progression, and the malignant potential of these lesions is…

Oncologymedicine.medical_specialtybiologybusiness.industryMedicine (all)PTEN Phosphohydrolasemedicine.diseaseptenGeneticInternal medicineGeneticsmedicinebiology.proteinHamartomaPTENHumansFemalebusinessHamartoma Syndrome MultipleGenetics (clinical)Human
researchProduct

Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention

2014

// Nicole M. Davis 1 , Melissa Sokolosky 1 , Kristin Stadelman 1 , Stephen L. Abrams 1 , Massimo Libra 2 , Saverio Candido 2 , Ferdinando Nicoletti 2 , Jerry Polesel 3 , Roberta Maestro 4 , Antonino D’Assoro 5 , Lyudmyla Drobot 6 , Dariusz Rakus 7 , Agnieszka Gizak 7 , Piotr Laidler 8 , Joanna Dulinska-Litewka 8 , Joerg Basecke 9 , Sanja Mijatovic 10 , Danijela Maksimovic-Ivanic 10 , Giuseppe Montalto 11,12 , Melchiorre Cervello 12 , Timothy L. Fitzgerald 13 , Zoya N. Demidenko 14 , Alberto M. Martelli 15 , Lucio Cocco 15 , Linda S. Steelman 1 and James A. McCubrey 1 1 Department of Microbiology and Immunology, Brody School of Medicine at East Carolina University Greenville, NC 27858 USA 2 …

Oncologymedicine.medical_specialtytherapy resistanceClass I Phosphatidylinositol 3-Kinasesmedicine.medical_treatmentBreast NeoplasmsReviewBiologyMechanistic Target of Rapamycin Complex 1PI3KMetastasisTargeted therapyPhosphatidylinositol 3-KinasesBreast cancerTARGETED THERAPYInternal medicinemedicinePTENHumansTargeted Therapy Therapy Resistance Mutations PI3K mTOR rapamycinskin and connective tissue diseasesProtein kinase BneoplasmsPI3K/AKT/mTOR pathwayRoswell Park Cancer InstituterapamycinTOR Serine-Threonine KinasesMTORPTEN PhosphohydrolaseCancerTargeted TherapyTherapy Resistancemedicine.diseaseTargeted Therapy; Therapy Resistance; Mutations; PI3K; mTOR; rapamycin3. Good healthErbB ReceptorsGene Expression Regulation NeoplasticOncologyMultiprotein ComplexesCancer researchbiology.proteinFemaleReceptor Epidermal Growth FactormutationRAPAMYCINProto-Oncogene Proteins c-aktMutationsSignal Transduction
researchProduct

Inverse solvent effects in the heterogeneous and homogeneous epoxidation of cis-2-heptene with [2-percarboxyethyl]-functionalized silica and meta-chl…

2014

The rate constants for the epoxidation of cis-2-heptene with [2-percarboxyethyl]-functionalized silica (1a) and meta-chloroperbenzoic acid (mCPBA) (1b) in different solvents have been determined at temperatures in the −10 to 40 °C range. The heterogeneous epoxidation exhibits a dependence of the reaction rate on solvent polarity opposite to its homogeneous counterpart and anomalous activation parameters in n-hexane, which are interpreted in terms of the surface-promoted solvent structure at the solid–liquid interface. The results show that highly polar solvents can strongly inhibit heterogeneous reactions performed with silica-supported reagents or catalysts.

Organic ChemistryPhotochemistrySilicon DioxideBiochemistryHepteneCatalysisHeptanesSolventReaction rateChlorobenzoateschemistry.chemical_compoundKineticsReaction rate constantchemistryReagentSolventsPolarEpoxy CompoundsHexanesThermodynamicsPhysical and Theoretical ChemistrySolvent effectsOxidation-ReductionOrganicbiomolecular chemistry
researchProduct

Signals involved in the early TH1/TH2 polarization of an immune response depending on the type of antigen.

1999

Abstract Background: The early production of distinct cytokines by epidermal cells (ECs) in response to antigen exposure may govern the development of T H1 -like immune responses, such as contact sensitivity, or T H2 -like immune responses, such as IgE-dependent allergies of the immediate type, depending on the type of antigen. Objective: The aim of this study was to compare the signals induced by protein allergens with those induced by haptens in ECs and subsequently in local draining lymph node cells (LNCs) or splenocytes. Methods: BALB/c mice were primed in vivo with the protein allergens ovalbumin or birch pollen or the haptens 2,4-dinitrofluorobenzene or trinitrochlorbenzene, respectiv…

Ovalbuminmedicine.medical_treatmentImmunologyImmunoglobulinsEnzyme-Linked Immunosorbent AssayPicryl ChlorideBiologyMiceImmune systemTh2 CellsAntigenmedicineDinitrochlorobenzeneImmunology and AllergyAnimalsRNA MessengerCells CulturedMice Inbred BALB CReverse Transcriptase Polymerase Chain ReactionCell PolarityEpithelial CellsT lymphocyteAllergensTh1 CellsInterleukin-10Interleukin 10OvalbuminBlotting SouthernKineticsCytokineImmunologybiology.proteinCytokinesPollenFemaleLymph NodesAntibodyHaptenHaptensSpleenSignal TransductionThe Journal of allergy and clinical immunology
researchProduct

The dark side of the moon: The PI3K/PTEN/AKT pathway in colorectal carcinoma

2009

Wild-type KRAS status is required but not sufficient to confer sensitivity to anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs) in colorectal cancer patients. As a consequence, one of the major challenges is to identify, in non-mutant KRAS patients, other markers that can predict lack of response to this therapy. Small series have investigated the clinical effect of PIK3CA mutations on resistance to anti-EGFR mAbs and discrepant results have been observed. Furthermore, PTEN loss in metastases may be predictive of resistance to anti-EGFR mAbs, even if PTEN determination is far from an immediate clinical application. The introduction of modulators of the PI3K/AKT/mTOR …

PTENCancer ResearchClass I Phosphatidylinositol 3-KinasesPrognosiSettore MED/06 - Oncologia MedicaColorectal cancerCetuximabColorectal NeoplasmPhosphoinositide 3-kinasemedicine.disease_causePhosphatidylinositol 3-KinasesAntineoplastic Combined Chemotherapy ProtocolsBiomarkers TumormedicineHumansPTENPanitumumabEpidermal growth factor receptorProtein kinase BPI3K/AKT/mTOR pathwayClass I Phosphatidylinositol 3-KinaseAntineoplastic Combined Chemotherapy ProtocolbiologyCetuximabAKTMTORPanitumumabPTEN PhosphohydrolaseAntibodies MonoclonalGeneral MedicinePrognosismedicine.diseaseErbB ReceptorsOncologyMutationbiology.proteinCancer researchReceptor Epidermal Growth FactorKRASPhosphatidylinositol 3-KinaseColorectal NeoplasmsProto-Oncogene Proteins c-aktHumanSignal Transductionmedicine.drug
researchProduct

Patrones de amplificación de EGFR en el glioblastoma, e identificación de biomarcadores implicados en sus principales vías de señalización

2022

En España, más de 4000 personas serán diagnosticadas anualmente con un tumor maligno cerebral que en su mayoría recaerán en el grupo que se denomina Gliomas Malignos. La mayoría son glioblastomas (grado IV) (GB), siendo estos el tipo más agresivo. Se espera que la supervivencia media para los pacientes tratados con protocolo estándar sea de alrededor de 15 meses. La esperanza de vida tan reducida se debe a que son tumores muy proliferativos y heterogéneos. Esto subraya la necesidad de buscar alternativas para mejorar su manejo. Los estudios de esta tesis se centran en caracterizar biomarcadores y alteraciones genéticas en los diferentes estatus de presentación del EGFR que permitan abordar …

PTENbiomarcadoressupervivenciaEGFRARF1metilación ADNUNESCO::CIENCIAS MÉDICASglioblastomaMVPADD3:CIENCIAS MÉDICAS [UNESCO]
researchProduct

Targeting the Cancer Initiating Cell: The Ultimate Target for Cancer Therapy

2012

An area of therapeutic interest in cancer biology and treatment is targeting the cancer stem cell, more appropriately referred to as the cancer initiating cell (CIC). CICs comprise a subset of hierarchically organized, rare cancer cells with the ability to initiate cancer in xenografts in genetically modified murine models. CICs are thought to be responsible for tumor onset, self-renewal/maintenance, mutation accumulation and metastasis. CICs may lay dormant after various cancer therapies which eliminate the more rapidly proliferating bulk cancer (BC) mass. However, CICs may remerge after therapy is discontinued as they may represent cells which were either intrinsically resistant to the or…

PTENgerminal mutationchemotherapeuticmedicine.medical_treatmentAntineoplastic AgentsPI3KTargeted therapyMetastasisMice03 medical and health sciencesTARGETED THERAPY0302 clinical medicineCancer stem cellNeoplasmsradiologicalDrug DiscoverymedicineAnimalsHumansPTENAkt; mTOR; PI3K; PTEN; Targeted therapy; Therapeutic sensitivityPI3K/AKT/mTOR pathway030304 developmental biologyPharmacologyBiological Products0303 health sciencesbiologyAKTMTORAktCD44Wnt signaling pathwayCancertargeted therapymedicine.disease3. Good healththerapeutic sensitivityxenografts030220 oncology & carcinogenesisImmunologymTORNeoplastic Stem CellsCancer researchbiology.proteinCurrent Pharmaceutical Design
researchProduct

Bone Metastasis in Renal Cell Carcinoma is Preprogrammed in the Primary Tumor and Caused by AKT and Integrin α5 Signaling

2015

Bone metastasis develops in 30% of all patients with renal cell carcinoma. We elucidated the mechanisms that lead to and predict bone metastasis of renal cell carcinoma.Nine renal cell carcinoma primary cell lines and 30 renal cell carcinoma tissue specimens (normal and tumor tissue) were collected from 3 patients with no metastasis and 10 with lung or bone metastasis within 5 years after nephrectomy. Cell migration was analyzed in a Boyden chamber and proliferation was assessed by bromodeoxyuridine incorporation. Adhesion to fibronectin, and collagen I and IV was determined after cell staining. The expression and/or activity of cellular signaling molecules was quantified by Western blot.Co…

Pathologymedicine.medical_specialtyUrologyBlotting WesternBone NeoplasmsIntegrin alpha5MetastasisExtracellular matrixCell MovementRenal cell carcinomaCell Line TumormedicineCarcinomaHumansCarcinoma Renal CellKidneybiologybusiness.industryTumor Suppressor ProteinsPTEN PhosphohydrolaseBone metastasisCell migrationDNA Neoplasmmedicine.diseaseKidney NeoplasmsGene Expression Regulation NeoplasticFibronectinmedicine.anatomical_structurebiology.proteinCancer researchbusinessProto-Oncogene Proteins c-aktSignal TransductionJournal of Urology
researchProduct